Tumor antigen peptide and use thereof
View Patent ↗Disclosed is a peptide consisting of the identical amino acid sequence or a substantially identical amino acid sequence to the amino acid sequence depicted in SEQ ID NO:4, wherein the peptide binds to an HLA antigen and is recognized by cytotoxic T cells. The peptide of the present invention can be used in vivo or in vitro as an agent for inducing CTL, that is, cancer vaccine, and exerts therapeutic or ameliorating effects on tumors such as osteosarcoma, renal cancer, and others. The peptide of the present invention is also useful as a tumor marker directed to tumors such as sarcoma, renal cancer, and others.
1. A composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 4 as an active ingredient and an effective amount of an adjuvant.
2. A composition comprising a recombinant expression vector comprising a nucleic acid encoding a peptide consisting of the amino acid sequence of SEQ ID NO: 4.
3. The composition according to claim 2 , wherein the nucleic acid is a polynucleotide consisting of the nucleic acid sequence of SEQ ID NO:3.
4. A composition comprising a nucleic acid encoding a peptide consisting of the amino acid sequence of SEQ ID NO: 4 and an effective amount of an adjuvant.
5. A method of producing an antigen presenting cell, comprising contacting in vitro:
(a) a peptide consisting of the amino acid sequence of SEQ ID NO: 4, or
(b) a nucleic acid comprising a polynucleotide encoding a peptide consisting of the amino acid sequence of SEQ ID NO: 4,
with a cell having antigen-presenting capability.
6. An antigen presenting cell produced by the method according to claim 5 .
7. A method of inducing a CTL, comprising contacting:
(a) a peptide consisting of the amino acid sequence of SEQ ID NO: 4, or
(b) a nucleic acid comprising a polynucleotide encoding a peptide consisting of the amino acid sequence of SEQ ID NO: 4,
with a peripheral blood lymphocyte.
8. A CTL induced by the method according to claim 7 .
9. An antibody which specifically binds to a peptide consisting of amino acid sequence of SEQ ID NO: 4.
10. An HLA tetramer which comprises a peptide consisting of the amino acid sequence of SEQ ID NO: 4 and a biotinylated HLA antigen.
11. A method of diagnosing a tumor in patient comprising:
contacting a sample obtained from the patient with the antibody of claim 9 ,
detecting binding between a peptide in the sample obtained from the patient and the antibody of claim 9 : and
determining that the patient is suffering from a tumor upon detecting that the peptide is bound to the antibody.
12. A method of treating cancer, comprising administering to an individual in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable carrier and one of the following:
(a) a peptide consisting of the amino acid sequence of SEQ ID NO: 4,
(b) a nucleic acid consisting of a polynucleotide encoding a peptide consisting of the amino acid sequence of SEQ ID NO: 4, or
(c) an antigen presenting cell produced by the method according to claim 5 .
13. A composition comprising a recombinant expression vector comprising a nucleic acid encoding a peptide consisting of the amino acid sequence of SEQ ID NO: 4 and a pharmaceutically acceptable carrier, wherein the composition has activity of inducing CTL when administered to a human or animal model of a human.
14. A peptide consisting of the amino acid sequence of SEQ ID NO; 4 and containing a substitution of an amino acid residue at position 2 or the C-terminus of SEQ ID NO: 4, wherein an amino acid residue at position 2 of SEQ ID NO: 4 is substituted by methionine, valine, isoleucine or glutamine, or an amino acid residue at the C-terminus of SEQ ID NO: 4 is substituted by leucine.
15. A pharmaceutical composition capable of inducing CIL, comprising:
an effective amount for inducing CTL of an isolated or synthesized peptide consisting of the amino acid sequence of SEQ ID NO: 4; and
a pharmaceutical acceptable carrier, wherein the pharmaceutical acceptable carrier is an adjuvant.
16. A method of diagnosing a tumor in a patient, comprising:
contacting a sample obtained from the patient with the HLA tetramer of claim 10 ;
detecting binding between a CTL in the sample obtained from the patient and the HLA tetramer; and
determining that the patient is suffering from a tumor upon detecting that the CTL is bound to the HLA tetramer,
wherein said HLA tetramer comprises a biotinylated HLA antigen and a peptide consisting of the amino acid sequence of SEQ ID NO:4.